Epidémiologie du cancer du sein, 2007. ,
DOI : 10.1016/j.lpm.2014.01.014
Institut national du cancer) Recommandations professionnelles. Cancer du sein infiltrant non métastatique ? Questions d'actualité ,
Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?, The Breast, vol.11, issue.5, 2002. ,
DOI : 10.1054/brst.2002.0462
uPA/PAI-1, Oncotype DX, Mammaprint. Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein, Bull Cancer, 2015. ,
DOI : 10.1007/s10269-014-2379-x
URL : http://dx.doi.org/10.1016/j.bulcan.2015.05.003
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67, J Imunol, 1984. ,
Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics, JNCI Journal of the National Cancer Institute, vol.100, issue.19, 2008. ,
DOI : 10.1093/jnci/djn309
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.3, 2008. ,
DOI : 10.1093/jnci/djm289
Ki67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat, 2012. ,
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, 2007. ,
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, 2008. ,
DOI : 10.1016/j.breast.2008.02.002
Ki67 in breast cancer: prognostic and predictive potential, The Lancet Oncology, vol.11, issue.2, 2010. ,
DOI : 10.1016/S1470-2045(09)70262-1
Strategies for subtypes ? dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, 2011. ,
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers, JNCI Journal of the National Cancer Institute, vol.101, issue.21, 2009. ,
DOI : 10.1093/jnci/djp335
Prognostic and predictive value of centrally reviewed Ki-67 labelling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole ,
Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, The Oncologist, vol.13, issue.12, 2008. ,
DOI : 10.1634/theoncologist.2008-0073
Is the Ki-67 labelling index ready for clinical use? Ann Oncol, 2011. ,
Référentiels de prise en charge des cancers du sein ,
Référentiel régional de prise en charge des cancers du sein non métastatiques. Mise à jour : septembre ,
Référentiel du cancer du sein (Recommandations pour la Pratique Clinique) ,
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer, Journal of Clinical Oncology, vol.25, issue.33, 2007. ,
DOI : 10.1200/JCO.2007.14.2364
Adjuvant breast cancer: which clinical and pathological characteristics en 2007? Bull Cancer, 2010. ,
Cancers infiltrants de bon pronostic : trop ou pas assez ? Mieux faire que les facteurs histopronostiques classiques TN et grade histopronostique : biochimie ou immunohistochimie ?, p.33, 2011. ,
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group, Genet Med, 2009. ,
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI Journal of the National Cancer Institute, vol.101, issue.10, 2009. ,
DOI : 10.1093/jnci/djp082
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014, Breast Care, vol.9, issue.3, 2014. ,
DOI : 10.1159/000363591
Ki67 labelling index can classify grade 2 breast cancers into two clinically distinct subgroups Breast Cancer Res Treat 2010. 39. Mengel M. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial, J Pathol, 2002. ,
DOI : 10.1007/s10549-010-1028-3
An International Ki67 Reproducibility Study, JNCI Journal of the National Cancer Institute, vol.105, issue.24, 2013. ,
DOI : 10.1093/jnci/djt306
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888090
How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists, PLoS ONE, vol.12, issue.5, 2012. ,
DOI : 10.1371/journal.pone.0037379.t003
Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer, Histopathology, vol.324, issue.6, 2012. ,
DOI : 10.1111/j.1365-2559.2012.04329.x
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group, JNCI Journal of the National Cancer Institute, vol.103, issue.22, 2011. ,
DOI : 10.1093/jnci/djr393
Est pour la pratique clinique et outil de l'Association française d'Assurance Qualité en anatomie pathologique (afAQap) pour la détermination de l'index Ki-67 en cas de marquage tumoral immunohistochimique hétérogène par plages, 2014. ,
Ki67 Antigen Référence du Produit : NCL-L-Ki67-MM1. Notice d'utilisation ,